Intra-articular Botox Type A Versus Corticosteroids in Knee Osteoarthritis

NCT ID: NCT02829281

Last Updated: 2016-07-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

105 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-07-31

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Introduction: Osteoarthritis of the knee is a very common disease. However there are few treatment options for these patients. Botulinum toxin type A is an option for chronic pain. If the investigators prove effectiveness of its use for intra-articular analgesia, Botulinum toxin type A can be useful for treat these patients.

Objective: Compare the effectiveness of the use of intra-articular corticosteroid versus Botulinum toxin type A in the treatment of patients with knee osteoarthritis.

Methods: A prospective controlled randomized double blind studied with three groups (n = 35 each group) of patients with symptomatic osteoarthritis of the knees receive intra-articular medication in a single moment will be undertaken. The three groups will be: Botulinum toxin type A Group: patients who receive 100 units of botulinum toxin; hexacetonide of triamcinolone Group: patients who receive 40mg of triamcinolone hexacetonide, and saline group: patients who receive 2ml of normal saline. Patients will be assessed by evaluators " blind " in 4 times during 12 weeks of follow-up with clinical assessment instruments (pain, quality of life questionnaire as short form 36 questionnaire) , functional ( WOMAC questionnaire) , and ultrasound (quantitative and semi quantitative measure of synovial hypertrophy and semi quantitative Power Doppler ) .The following statistical tests will be used : Student's t test, Mann - Whitney , chi- square test and ANOVA for repeated measures . Will be considered as statistical significance the difference of 5 %.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Knee Osteoarthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Botulinum toxin group

Patients will receive a intervention with joint injection of 100 units of botulinum toxin

Group Type EXPERIMENTAL

Botulinum Toxin Type A

Intervention Type DRUG

Joint injection of Botulinum Toxin Type A

Corticosteroid group

Patients will receive a intervention with joint injection of 40mg of triamcinolone hexacetonide (corticosteroid)

Group Type ACTIVE_COMPARATOR

Triamcinolone hexacetonide

Intervention Type DRUG

Joint injection of triamcinolone hexacetonide

Saline Group

Patients will receive a joint injection of 2ml of normal saline

Group Type PLACEBO_COMPARATOR

Saline

Intervention Type DRUG

Joint injection of Saline

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Botulinum Toxin Type A

Joint injection of Botulinum Toxin Type A

Intervention Type DRUG

Triamcinolone hexacetonide

Joint injection of triamcinolone hexacetonide

Intervention Type DRUG

Saline

Joint injection of Saline

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age above 50 years
* diagnose of knee osteoarthritis using clinics and radiographic criteria
* pain for more than 6 months
* analogic visual scale among 4 to 8
* patients who agree to sign informed consent

Exclusion Criteria

* secondary osteoarthritis
* skin lesion
* use of intraarticular corticosteroid in the last 3 months
* use of oral corticosteroid in the last 30 days
* Kellgren Lawrence I or IV
* inflammatory arthritis
* neuromuscular disease
* use of aminoglycoside antibiotics
* metalic prosthesis in knee
* peripheric neuropathy
* serious cardiovascular or pulmonary disease
* serious disorder of coagulation
* pregnancy or breastfeeding
* infections
* use of wheelchair
Minimum Eligible Age

50 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Federal University of São Paulo

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jamille Godoy Mendes

MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Universidade Federal de Sao Paulo

São Paulo, São Paulo, Brazil

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Brazil

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jamille G Mendes, MD

Role: CONTACT

551155764239

Rita NV Furtado, MD

Role: CONTACT

1155764239

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CEP UNIFESP - 319915

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Botulinum Toxin Type A for Neuroma Pain
NCT01374191 WITHDRAWN PHASE2